Morepen Laboratories (MOREPENLAB) | Stock Overview & Key Data
Morepen Laboratories Performance Comparison
Stock Range
Today's Range
Low: ₹46.16
High: ₹48.85
on August 13, 2025
52 Week Range
Low: ₹42.00
High: ₹100.90
on April 7, 2025
on September 10, 2024
All-Time High: ₹175.00 on October 11, 1999
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR25.5B
EPS
2.20
P/E Ratio (TTM)
21.10
Forward P/E
N/A
P/B Ratio
2.33
PEG Ratio
N/A
Div. Yield
N/A
ROE
9.94%
Beta
0.788
Debt to Equity
8.85
Financial Highlights
Profitability
Gross Margin
32.22%
Operating Margin
4.55%
Profit Margin
5.14%
Returns and Earnings
Return on Assets (TTM)
6.64%
Return on Equity (TTM)
9.94%
EBITDA
INR1.9B
Net Income (TTM)
INR926.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR32.87
Quarterly Revenue Growth (YoY)
-6.30%
Quarterly Earnings Growth (YoY)
-70.30%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Morepen Laboratories MOREPENLAB | 25.46B Small-cap | -17.52% | -25.66% | -22.73% | -16.58% | -41.10% | -22.93% | 36.14% | 93.00% |
| Sun Pharmaceutical SUNPHARMA | 3.81T Large-cap | -0.61% | -3.59% | -3.80% | -4.23% | -14.17% | -7.71% | 78.44% | 202.13% |
| Divi's Laboratories DIVISLAB | 1.59T Large-cap | -6.99% | -12.06% | 0.32% | -0.15% | -1.84% | 28.64% | 61.27% | 83.57% |
| Sun Pharma Advanced SPARC | 46.41B Small-cap | -2.63% | -11.98% | -4.53% | -3.07% | -29.29% | -33.23% | -41.02% | -21.77% |
| Aarti Drugs AARTIDRUGS | 44.67B Small-cap | 1.65% | 1.81% | 14.25% | 24.49% | 7.45% | -1.48% | 9.59% | -37.52% |
| Sequent Scientific SEQUENT | 43.53B Small-cap | -2.62% | -6.11% | 2.95% | 14.81% | -5.65% | 23.40% | 60.75% | 35.04% |
Ownership & Short Interest
Insider Ownership
42.69%
Institutional Ownership
1.37%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
4M
Average 90-Day Volume
3M
Morepen Laboratories Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Morepen Laboratories would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is MOREPENLAB's 52-week high and low?
- In the last 52 weeks, Morepen Laboratories reached a high of ₹100.90 (on September 10, 2024) and a low of ₹42.00 (on April 7, 2025).
- What is the market cap and P/E ratio for MOREPENLAB?
- Curious about Morepen Laboratories's size and valuation? Its market capitalization stands at 25.46B. When it comes to valuation, the P/E ratio (trailing twelve months) is 21.10, and the forward P/E (looking ahead) is N/A.
- Does MOREPENLAB pay dividends? If so, what's the yield?
- As for dividends, Morepen Laboratories isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Morepen Laboratories's main competitors or similar companies to consider before investing?
When looking at Morepen Laboratories, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.81T Healthcare Drug Manufacturers - Specialty & Generic -7.71% 78.44% Divi's Laboratories
DIVISLAB1.59T Healthcare Drug Manufacturers - Specialty & Generic 28.64% 61.27% Sun Pharma Advanced
SPARC46.41B Healthcare Drug Manufacturers - Specialty & Generic -33.23% -41.02% Aarti Drugs
AARTIDRUGS44.67B Healthcare Drug Manufacturers - Specialty & Generic -1.48% 9.59% Sequent Scientific
SEQUENT43.53B Healthcare Drug Manufacturers - Specialty & Generic 23.40% 60.75% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Morepen Laboratories Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Morepen Laboratories's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 9.94%, the Debt to Equity ratio from the most recent quarter is 8.85, and its Gross Profit Margin stands at 32.22%.
- What is the recent revenue and earnings growth for MOREPENLAB?
- Looking at Morepen Laboratories's growth, its revenue over the trailing twelve months (TTM) was INR18B. Compared to the same quarter last year (YoY), quarterly revenue grew by -6.30%, and quarterly earnings saw a YoY growth of -70.30%.
- How much of MOREPENLAB stock is held by insiders and institutions?
- Wondering who owns Morepen Laboratories stock? Company insiders (like executives and directors) hold about 42.69% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 1.37%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.